Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 1.00 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30537994 | 1.00 | BRPF1 (1.00) | BRPF1BRD4OPRM1OPRD1OPRK1 | |
| SCHEMBL5230478 | 0.81 | BRPF1 (0.69) | BRPF1BRD4OPRM1OPRD1OPRK1 | |
| SCHEMBL13158906 | 0.79 | BRPF1 (0.66) | BRPF1BRD4CREBBPTTRCES1 | |
| SCHEMBL1364964 | 0.78 | BRPF1 (0.64) | BRPF1BRD4OPRM1GABRA1GABRG2 | |
| SCHEMBL11455051 | 0.78 | BRPF1 (0.63) | BRPF1BRD4OPRM1OPRD1OPRK1 | |
| SCHEMBL4158789 | 0.77 | BRPF1 (0.62) | BRPF1BRD4OPRK1HSD17B3KMT2A | |
| SCHEMBL31298630 | 0.77 | BRPF1 (0.62) | BRPF1BRD4OPRM1OPRD1OPRK1 | |
| SCHEMBL10720372 | 0.77 | BRPF1 (0.62) | BRPF1BRD4OPRM1OPRD1OPRK1 | |
| SCHEMBL28008000 | 0.77 | BRPF1 (0.62) | BRPF1BRD4OPRM1OPRD1OPRK1 | |
| Ammonia Solution, Strong SCHEMBL9389187 | 0.77 | BRPF1 (0.62) | BRPF1BRD4OPRM1GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109535087-B | Synthetic method of quinoxaline-2 (1H) -ketone C-3 site aroyl compound | 湖南科技学院 | 2020-07-31 | — | — | CN | disclosed |
| CN-109535086-B | Synthetic method of quinoxaline-2 (1H) -ketone C-3 carboxylate compound | 湖南科技学院 | 2020-05-05 | — | — | CN | disclosed |
| EP-1555266-B1 | REMEDIES OR PREVENTIVES FOR URINARY INCONTINENCE AND MORPHINAN DERIVATIVES HAVING NITROGEN-CONTAINING HETEROCYCLIC GROUP | TORAY INDUSTRIES (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7320984-B2 | Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group | TORAY INDUSTRIES, INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-20060040970-A1 | Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group | TORAY INDUSTRIES, INC. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1583745-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1555266-A1 | REMEDIES OR PREVENTIVES FOR URINARY FREQUENCY OR URINARY INCONTINENCE AND MORPHINAN DERIVATIVES HAVING NITROGEN-CONTAINING HETEROCYCLIC GROUP | TORAY INDUSTRIES, INC. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-4764512-A | Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1988-08-16 | — | — | US | disclosed |
| EP-0118982-A1 | Organic phosphorous quinoxalinone and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-09-19 | — | — | EP | disclosed |
| US-RE30415-E | ANTIINFLAMMATORY AGENTS, ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-RE30314-E | ANTIINFLAMMATORY, ANTITHROMBOTIC | ELI LILLY AND COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4133884-A | Substituted pyrroloquinoxalinones and diones used in treating inflammation in warm blooded mammals | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4087527-A | ANTIINFLAMMATORY AND ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4075206-A | ANTIINFLAMMATORY, ANTITHROMBOTIC | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | BRPF1 4134/4885BRD4 2189/4885OPRM1 427/4885 |
| US-20060040970-A1 | Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group | MYH10, H1-10, MB | BRPF1 3338/4885BRD4 2736/4885OPRM1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.